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Limited utility of tissue micro-arrays 
in detecting intra-tumoral heterogeneity 
in stem cell characteristics and tumor 
progression markers in breast cancer
Pascale Kündig1, Charlotte Giesen2, Hartland Jackson2, Bernd Bodenmiller2, Bärbel Papassotirolopus3, 
Sandra Nicole Freiberger1, Catharine Aquino4, Lennart Opitz4 and Zsuzsanna Varga1* 
Abstract 
Background: Intra-tumoral heterogeneity has been recently addressed in different types of cancer, including breast 
cancer. A concept describing the origin of intra-tumoral heterogeneity is the cancer stem-cell hypothesis, propos-
ing the existence of cancer stem cells that can self-renew limitlessly and therefore lead to tumor progression. Clonal 
evolution in accumulated single cell genomic alterations is a further possible explanation in carcinogenesis. In this 
study, we addressed the question whether intra-tumoral heterogeneity can be reliably detected in tissue-micro-arrays 
in breast cancer by comparing expression levels of conventional predictive/prognostic tumor markers, tumor progres-
sion markers and stem cell markers between central and peripheral tumor areas.
Methods: We analyzed immunohistochemical expression and/or gene amplification status of conventional prognos-
tic tumor markers (ER, PR, HER2, CK5/6), tumor progression markers (PTEN, PIK3CA, p53, Ki-67) and stem cell mark-
ers (mTOR, SOX2, SOX9, SOX10, SLUG, CD44, CD24, TWIST) in 372 tissue-micro-array samples from 72 breast cancer 
patients. Expression levels were compared between central and peripheral tumor tissue areas and were correlated to 
histopathological grading. 15 selected cases additionally underwent RNA sequencing for transcriptome analysis.
Results: No significant difference in any of the analyzed between central and peripheral tumor areas was seen with 
any of the analyzed methods/or results that showed difference. Except mTOR, PIK3CA and SOX9 (nuclear) protein 
expression, all markers correlated significantly (p < 0.05) with histopathological grading both in central and peripheral 
areas.
Conclusion: Our results suggest that intra-tumoral heterogeneity of stem-cell and tumor-progression markers can-
not be reliably addressed in tissue-micro-array samples in breast cancer. However, most markers correlated strongly 
with histopathological grading confirming prognostic information as expression profiles were independent on the 
site of the biopsy was taken.
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Background
Different types of cancer, including breast cancer, were 
found to present intra-tumoral heterogeneity, which can 
occur as genetic, phenotypic or functional diversity in 
spatial or temporal patterns [1]. The two most commonly 
accepted concepts describing the origin of tumor hetero-
geneity are the cancer stem cell (CSC) hypothesis and the 
Darwinian clonal evolution model [2, 3]. Both thesis con-
sider gain of proliferative potential through single cells 
that acquired multiple molecular alterations. The Dar-
winian clonal evolution model proposes natural selection 
through varying degrees of genetic instability, leading to 
multiple subpopulations with different genetic aberra-
tions. On the other hand, the cancer stem cell hypothesis 
posits the existence of a small population of tumorigenic 
cells within a tumor, that can self-renew limitlessly and 
therefore induces tumor growth, disease progression, 
propensity for metastasis and the generation of heteroge-
neity [3–5]. Moreover, cancer stem cells lead to therapy 
resistance [5–7]. In 2003, Al-Hajj et al. first described the 
presence of cancer stem cells in human breast cancer [6, 
8].
When using core needle biopsy or fine-needle aspira-
tions for tumor diagnostics only a small amount of tis-
sue is examined. Therapeutic decisions are based on 
those single tumor samples. Accordingly, the findings 
of regional intra-tumoral heterogeneity of biomark-
ers query the significance of single biopsy interpreta-
tions with implications for accurate tumor classification 
[9–11]. Huebschman et al. previously examined adjacent 
cells in triple negative breast cancer at which a significant 
molecular heterogeneity, including as well markers of 
the “stem cell” type, was found [10]. Allott et al. revealed 
spatial heterogeneity to be a source of core-to-core dis-
cordance in status of estrogen receptor (ER), progester-
one receptor (PR), and human epidermal growth factor 
2 (HER2) on tissue micro arrays (TMAs) when analyzed 
using automated digital image. They therefore suggested 
intra-tumoral heterogeneity to have possible implications 
for breast cancer classifications [11]. To optimize therapy, 
molecular biomarkers are required, that exactly predict 
clinical disease outcomes and can be targets of molecular 
therapies [12].
In our study, we addressed the question whether intra-
tumoral heterogeneity of breast stem cell and tumor pro-
gression markers can be reliably detected in TMA based 
tumor samples by comparing protein and gene expres-
sion levels between central and peripheral tumor parts. 
For this purpose, a special TMA was constructed con-
taining peripheral and central primary breast cancer and 
as well as available also metastatic samples. Furthermore, 
we proofed central and peripheral areas whether they 
bear the same prognostic information regarding stem 
cell and tumor progression markers on the base of histo-
pathological grading.
Methods
Patient cohort
In this study, a special tissue micro array (TMA) was 
constructed using 372 formalin-fixed, paraffin embed-
ded (FFPE) tissue samples from 72 breast cancer patients. 
The cohort contained 372 samples from the Institute of 
Pathology and Molecular Pathology, University Hospital 
of Zurich, collected between 1998 and 2011. Samples for 
the TMA were punched from central and peripheral pri-
mary tumor tissue areas in all n = 72 cases. The distance 
between central and peripheral areas was on average 
1 cm. Samples from axillary lymph node or skin metas-
tases were available in n = 11 cases. Clinico-pathological 
data such as histological grading, subtype and tumor/
nodal stage and information about patient follow-up 
could be retrieved from the database of the Institute of 
Pathology and Molecular Pathology, University Hospital 
of Zurich. Additional data on patient survival was pro-
vided by the Breast Center Seefeld, Zurich.
Clinico‑pathological parameters
In total, 57 of 72 (79%) cases were invasive ductal carci-
nomas (NST, non-special type) (G1: n = 16, G2: n = 16, 
G3: n = 25), n = 9 (13%) cases were invasive lobular car-
cinomas (G1: n = 0, G2: n = 8, G3: n = 1) and n = 5 (7%) 
tumors were classified as other histological subtypes. 
Information on histological subtype was missing in n = 1 
(1%) case.
Altogether, pT stage was available in 67 of 72 cases 
(93%). The information was missing for n = 5 (7%) 
patients. N = 31 (43%) tumors were staged pT1 (G1: 
n = 12, G2: n = 8, G3: n = 11), n = 26 (36%) tumors were 
staged pT2 (G1: n = 6, G2: n = 10, G3: n = 10), n = 9 (13%) 
tumors were staged pT3 (G1: n = 0, G2: n = 5, G3: n = 4) 
and n = 1 (1%) tumor was classified pT4 (G1: n = 0, G2: 
n = 0, G3: n = 1).
Nodal stage was available in n = 63 cases. The informa-
tion was missing in n = 9 (13%) patients. N = 28 (39%) 
cases were nodal negative (pN0, G1: n = 11, G2: n = 8, 
G3: n = 9). Of the nodal positive patients, n = 26 (36%) 
tumors were classified as pN1 (G1: n = 7, G2: n = 7, G3: 
n = 12), n = 5 (7%) tumors were classified as pN2 (G1: 
n = 1, G2: n = 3, G3: n = 1) and n = 4 (6%) tumors were 
staged as pN3 (G1: n = 0, G2: n = 2, G3: n = 3).
Clinico-pathological parameters are summarized in 
Table 1.
Tissue micro array (TMA)
Formalin-fixed, paraffin embedded (FFPE) tissue sam-
ples from 72 breast cancer patients were arranged into 
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one tissue micro array (TMA 208) using a method of 
construction previously described [13, 14]. From each 
patient (n = 72) two tissue cores of central tumor parts, 
as well as two tissue cores of peripheral tumor parts 
and at least one core of normal tissue were punched 
and added to the TMA. Areas to be selected for the 
TMA were determined on hematoxylin and eosin (HE) 
stained large tissue sections from routine diagnostic 
slides. Additionally, in 15% of cases (n = 11) two cores 
from lymph node metastasis and in 1% of cases (n = 1) 
two cores of skin metastasis were added to the TMA. 
Selection of tumor areas were processed for the TMA 
in the same way as with the primary tumors.
Tissue cores were grouped per patient and according 
to the histopathological grading [15]. Of 72 cases 19 were 
well differentiated (G1), n = 26 were moderately differen-
tiated (G2) and n = 27 were poorly differentiated (G3).
Immunohistochemistry
All immunohistochemical stains were performed in the 
Immunohistochemistry Laboratory of the Institute of 
Pathology and Molecular Pathology, University Hospital 
Zurich, with following clones and pretreatment modali-
ties using the automated Ventana Benchmark stain sys-
tem (Additional file 1: Table S1).
Scoring of immunohistochemical stains
The expressions of E-cadherin, p63, CK5/6, CD24, mTOR 
and PIK3CA were scored with a two-tiered scoring sys-
tem (negative vs. positive) being membranous and/or 
nuclear positive.
The expressions of SLUG, SOX2, SOX9, SOX10, 
PTEN, TWIST, p53 and CD44 were scored with a three-
tiered scoring system (negative, ≤ 50% of the cells posi-
tive, > 50% of the cells positive), being cytoplasmic and/or 
nuclear positive.
Table 1 Clinico-pathological parameters
n = 72s Histological grading
G1 G2 G3 Total
n % n % n % n %
Type of tissue
 Tumor center 19 100 26 100 27 100 72 100
 Tumor periphery 19 100 26 100 27 100 72 100
 Normal tissue 19 100 26 100 27 100 72 100
 Lymph node metastasis 1 5 6 23 4 15 11 15
 Skin metastasis 0 0 1 4 0 0 1 1
 Total 19 100 26 100 27 100 72 100
Histological subtype
 Invasive ductal 16 84 16 62 25 93 57 79
 Invasive lobular 0 0 8 31 1 4 9 13
 Other 3 16 2 8 0 0 5 7
 Unknown 0 0 0 0 1 4 1 1
 Total 19 100 26 100 27 100 72 100
pT stage
 pT1 12 63 8 31 11 41 31 43
 pT2 6 32 10 38 10 37 26 36
 pT3 0 0 5 19 4 15 9 13
 pT4 0 0 0 0 1 4 1 1
 Unknown 1 5 3 12 1 4 5 7
 Total 19 100 26 100 27 100 72 100
pN stage
 pN0 11 58 8 31 9 33 28 39
 pN1 7 37 7 27 12 44 26 36
 pN2 1 5 3 12 1 4 5 7
 pN3 0 0 2 8 2 7 4 6
 Unknown 0 0 6 23 3 11 9 13
 Total 19 100 26 100 27 100 72 100
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The membranous expressions of HER2 and EGFR were 
scored with a four-tiered scoring system (negative, ≤ 10% 
positive, > 10% but incomplete positive, strong circular 
positivity in > 10% of the cells), according to current diag-
nostic guidelines as score 0, 1+, 2+, 3+ [16].
The nuclear expressions of ER, PR and Ki-67 were 
scored with a scoring system representing the estimated 
proportion of positive tumor cells (negative, 10% positive, 
20% positive, 30% positive, 40% positive, 50% positive, 
60% positive, 70% positive, 80% positive, 90% positive, 
100% positive).
Representative stains from each stain are shown in 
Fig. 1.
Fluorescent in situ hybridization (FISH) reaction
HER2
The HER2 gene was tested by using a dual fluorescence 
kit (PathoVysion, Vysis, Abbott AG, Diagnostic Division 
Baar, Switzerland) containing the HER2 gene (17q11.2-
q12, directly labeled with fluorescent spectrum orange) 
and CEP17 (17p11.1-q11.1, labeled with fluorescent 
spectrum green). The whole procedure was carried out 
using the PathoVysion probes on the fully automated 
Leica Bond autostainer (Leica Biosystems, Nunningen, 
Switzerland).
PTEN
The PTEN gene was visualized by the Vysis PTEN probe 
(Vysis, Abbott AG, Diagnostic Division Baar, Switzer-
land). The kit contained the PTEN gene (10q23) labelled 
with orange and the CEP10 probe (10p11.1-q11.1) 
labeled with green. The procedure was carried out using 
the Leica Bond autostainer according to the manufactur-
er’s instructions.
PIK3CA
The Vysis PIK3CA dual probe (labelled as green, locus 
3q26.32) together with the CEP3 probe (labelled as 
orange, locus 3p11.1-q11.1) were used (Vysis, Abbott 
AG, Diagnostic Division Baar, Switzerland). The proce-
dure was done on the Leica Bond autostainer.
Scoring of fluorescent in situ hybridization (FISH) reactions
HER2
The 2013 ASCO-CAP guidelines were used for interpret-
ing the signals in the FISH tests [16]. The number of sig-
nal copies and the ratios (HER2/CEP17) were calculated 
for each probe. Gene copies (> 6 in at least 10% of the 
tumor surface) or cluster formations (small clusters ~ 6 
copies, larger clusters ~ 12 copies) were defined as ampli-
fied. Similarly, a ratio > 2 was defined as amplified (posi-
tive), a ratio < 2 was set as negative (Fig. 2).
PTEN, PIK3CA
Scoring was done in an analogous way as in HER2 FISH 
assays described above.
Illustrative areas of FISH reactions are shown in Fig. 2.
Transcriptome (mRNA) analysis
15 cases, five from each histological grading (5 cases G1, 
5 cases G2, 5 cases G3) were selected for transcriptome 
analysis using next generation sequencing. The same cen-
tral and peripheral areas of the paraffin blocks that were 
used for TMA construction were punched for recep-
tion of material for RNA extraction. HE slide controls 
were used for the area selection for the mRNA tissue 
preparation.
Paraffin blocks were punched both in the center and 
in the tumor periphery. RNA was isolated from these 
punches using the Maxwell FFPE RNA isolation kit (Pro-
mega) according to the manufacturer’s manual in the 
Institute of Pathology and Molecular Pathology Univer-
sity Hospital Zürich. The RNA amount was quantified by 
Qubit measurement. The fragment size of the RNA was 
determined by the  DV200 analysis using the bioanalyzer. 
Transcriptome analysis was performed at the Functional 
Genomics Center Zurich, Switzerland.
The SMARTer Stranded Total RNA-Seq Kit-Pico Input 
Mammalian (Clontech Laboratories, Inc., A Takara Bio 
Company, California, USA) was used in the prepara-
tion of libraries for sequencing. No fragmentation was 
performed. Total RNA samples (10  ng) were reverse-
transcribed using random priming into double-stranded 
cDNA in the presence of a template switch oligo (TSO). 
When the reverse transcriptase reaches the 5′ end of the 
RNA fragment, the enzyme’s terminal transferase activ-
ity adds non-templated nucleotides to the 3′ end of the 
cDNA. The TSO pairs with the added non-templated 
nucleotide, enabling the reverse transcriptase to continue 
replicating to the end of the oligonucleotide. This resulted 
in a cDNA fragment that contains sequences derived 
from the random priming oligo and the TSO. PCR ampli-
fication using primers binding to these sequences was 
performed. The PCR added full-length Illumina adapters, 
including the index for multiplexing. Ribosomal cDNA 
was cleaved by ZapR in the presence of the mammalian-
specific R-Probes. Remaining fragments were enriched 
with a second round of PCR amplification using primers 
designed to match Illumina adapters.
The quality and quantity of the enriched libraries were 
validated using the Tapestation (Agilent, Waldbronn, 
Germany). The product is a smear with an average frag-
ment size of approximately 360  bp. The libraries were 
normalized to 10  nM in Tris–Cl 10  mM, pH8.5 with 
0.1% Tween 20. The libraries were sequenced single end 
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Fig. 1 Representative immunohistochemical stains according to biological features. a Conventional predictive/prognostic markers, b tumor 
progression markers, c stem cell markers
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125 bp using the Illumina HiSeq 4000 (Illumina, Inc, Cal-
ifornia, USA).
The RNA-seq data analysis consisted of the following 
steps:
Read-alignment was done with STAR (version 2.5.3a). 
As reference, we used the Ensembl genome build 
GRCh38.p10. With the gene annotations of Ensembl 
release 91.
The STAR alignment options were “–outFilter-
Type BySJout–outFilterMatchNmin 30–outFilter-
MismatchNmax 10–outFilterMismatchNoverLmax 
0.05–alignSJDBoverhangMin 1–alignSJoverhangMin 
8–alignIntronMax 1,000,000–alignMatesGapMax 
1,000,000–outFilterMultimapNmax 50”.
Gene expression values were computed with the func-
tion featureCounts from the R package Rsubread.
Differential expression was computed using the gen-
eralized linear model implemented in the Bioconductor 
package EdgeR. In the statistical model, we considered as 
factors the tumor area and the patient [17–19].
Statistical analysis
IBM SPSS Statistics 23 was used for statistical analysis of 
the correlations of intratumoral heterogeneity and grad-
ing to stem cell characteristics and tumor progression 
markers. Frequency distribution was showed using cross-
tabs as a multivariate statistical method. Chi square and 
Spearman rank correlation coefficient were calculated to 
estimate the strength of the correlation as well as fisher’s 
exact test. p-value < 0.05 were interpreted as statistically 
significant. Correlation matrix graphics were constructed 
using the Correlation Matrix STHDA.com online 
software.
Results
Intra‑tumoral heterogeneity
Expression levels of all markers were compared between 
tissue cores of central and peripheral tumor parts to 
assess intra-tumoral heterogeneity. Comparison with tis-
sue samples of lymph node metastasis was limited due to 
small number of samples. All three groups of markers (1) 
conventional predictive markers (ER, PR, HER2, EGFR 
and CK5/6), (2) tumor progression markers (PTEN, 
PIK3CA, p53, Ki-67) and (3) stem cell markers (E-cad-
herin, mTOR, SOX2, SOX9, SOX10, SLUG, CD44, CD24 
and TWIST) were analyzed. There was no significant 
difference in the expression level in any of the analyzed 
markers in terms of central and peripheral tumor areas. 
Central and peripheral spots showed a high correlation 
(as detailed in Additional file  2: Table  S2). Additionally, 
there was a complete concordance between central tumor 
areas and metastatic lesions in all marker expression.
Correlation to histological grading
All previously described markers were correlated to his-
topathological grading. Conventional parameters (ER, 
Fig. 2 Representative areas of FISH reactions with negative and amplified samples: HER2, PTEN, PIK3CA
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PR, HER2 status, EGFR, CK5/6), as expected significantly 
correlated to histological grading (p < 0.05).
Tumor progression markers as PIK3CA FISH amplifi-
cation, p53 and Ki-67 immunohistochemical expression 
showed a strong significant correlation between histo-
logical grading and expression level (p < 0.0001). PTEN 
both with immunohistochemistry and FISH correlated 
slightly with histological grading (p < 0.05). PIK3CA pro-
tein expression did not show significant correlation to 
grading.
Among stem cell markers, a strong significant correla-
tion between histological grading and expression level 
was found with E-cadherin, SOX2, SOX10, CD24 and 
TWIST. Furthermore, a slight significant correlation 
was seen with SOX9 (cytoplasmatic), SLUG (cytoplas-
matic) and CD44. SOX9 (nuclear) and mTOR expression 
showed no correlation to histological grading.
Details of the individual stains are shown in Additional 
file 3: Table S3 and in Figs. 3a, b, 4a–c.
Correlation of conventional prognostic/predictive markers 
with stem cell and progression markers
Among the conventional predictive markers, a strong sig-
nificant correlation was found between estrogen receptor 
and all the other conventional predictive markers, as well 
as between progesterone receptor and EGFR, HER2 IHC 
and CK5/6, between HER2 IHC and CK5/6 and HER2 
FISH and between EGFR and CK5/6.
When correlated to tumor progression markers, a 
slight significant correlation was seen between estrogen 
receptor and PTEN (IHC and FISH), estrogen recep-
tor and PIK3CA (IHC) as well as between progesterone 
receptor and PIK3CA (IHC). Comparison of ER and PR 
to Ki-67, HER2 IHC to PTEN FISH, p53 and Ki-67, as 
well as comparison of EGFR to p53 and Ki-67 and CK5/6 
to PIK3CA, p53 and Ki-67 revealed a strong significant 
correlation.
The correlation of conventional predictive markers 
to stem cell markers showed numerous significant cor-
relations. Especially the hormone receptors and EGFR 
revealed a strong significant correlation to stem cell 
markers.
Details of stain distribution and significant correlations 
are shown in Additional file 4: Table S4 and in Fig. 5a, b.
Correlation of tumor progression markers to other markers
Correlation of the tumor progression markers PTEN, 
PIK3CA, p53 and Ki-67 to other tumor progression 
markers as well as to conventional predictive markers 
and stem cell markers was investigated.
Among the tumor progression markers, a significant 
correlation was only seen between PTEN and PIK3CA 
(IHC) and p53 and PIK3CA (IHC).
Tumor progression markers and stem cell markers 
revealed numerous strong significant correlations with 
each other. No significant correlations could be seen 
between tumor progression markers and SOX9 and 
CD44.
Comparison of tumor progression markers to conven-
tional predictive markers is described above.
Details of stain distribution and significant correlations 
are shown in Additional file 5: Table S5 and in Fig. 6a, b.
Comparison of stem cell markers to other markers
Comparison of stem cell markers to conventional mark-
ers and tumor progression markers is described above.
Fig. 3 Graphical illustration of association between histological grading (a) and conventional prognostic/predictive markers (b) and tumor 
progression markers. p-values reflect Fisher’s exact test results
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Fig. 4 a–c Graphical illustration of association between histological grading and stem cell markers. p-values reflect Fisher’s exact test results
Fig. 5 Graphical illustration of stain distribution (a) and correlation (b) among prognostic-predictive markers. Bars indicate mean values
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Among the stem cell markers numerous significant 
correlations were found. No significant correlation was 
seen between SOX10 and other stem cell markers.
Details of stain distribution and significant correlations 
are shown in Additional file 6: Table S6 and in Fig. 7a, b.
Transcriptome (mRNA) analysis
The sample clustering for the 2000 most variable genes in 
the experiment of the mRNA expression profiles shows 
that samples from the same patient are grouping together 
(Fig. 8). There is no indication for a differential expression 
signature between tumor areas based on the explorative 
cluster analysis. The sample to sample correlation illus-
trated in Fig. 9a confirms a strong positive correlation for 
all patient sample pairs included in this study. Focusing 
only on the 100 most variable genes provides very similar 
results (Fig. 9b).
Furthermore, the expression profiles between cen-
tral and peripheral tumor areas were directly compared 
considering the patient as an additional factor in the lin-
ear model to remove the influence of different genetic 
backgrounds. The resulting p value histogram for all 
genes is following a uniform distribution (Fig.  10). This 
suggests that there is no gene signature which signifi-
cantly differs between both tumor areas. No candidate 
gene was detected by applying a fold-change cut off > 2 
and p-value ≤ 0.01.
Based on these results, there is no indication for any 
differentially expressed gene between periphery and 
center in this data.
Discussion
In our study, we addressed the question whether a tissue 
micro array based approach can sufficiently detect intra-
tumoral heterogeneity in stem cell and tumor progres-
sion markers in breast cancer by comparing expression 
levels between central and peripheral tumor parts. Our 
results suggest, that based on protein and DNA expres-
sion levels in tissue micro array core sections, no reliable 
distinction could be determined.
We are not aware of any similar approach in the liter-
ature describing the value of TMA in the intra-tumoral 
Fig. 6 Graphical illustration of stain distribution (a) and correlation (b) among tumor progression markers. Bars indicate mean values
Fig. 7 Graphical illustration of stain distribution (a) and correlation (b) among stem cell markers. Bars indicate mean values
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Fig. 8 Heatmap showing the most variable 2000 genes in the RNA-Seq data. Sample and gene clustering was applied. The color indicates the 
log2-foldchange in comparison to the overall samples mean of the corresponding gene
(See figure on next page.)
Fig. 9 Heatmap showing the sample to sample correlation based on Kendall’s rank correlation coefficient for a all expressed genes (mean 
count > 20) and b 100 most variable genes across all samples
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heterogeneity of stem cell and tumor progression mark-
ers in breast cancer.
Our findings partially contradict previous studies 
revealing intra-tumoral heterogeneity in breast cancer in 
tissue section based in the expression level of prognostic 
markers [9]. The finding of intra-tumoral heterogeneity in 
Ki-67 expression levels was confirmed in a recent study 
by Focke et  al. [20]. On the other hand, when compar-
ing tissue array-based measures of ER and PR status with 
immunohistochemistry, intra-tumoral heterogeneity, 
although present, did not affect exact tumor classifica-
tion [21]. Similarly, in a study of Yang et al. investigating 
spatial heterogeneity of breast cancer stem cell markers, 
few patients revealed intra-tumoral heterogeneity, but no 
association with prognosis was seen [22].
Contrariwise, our results are in accordance to the 
data of Alkatout et al. where as well no difference of the 
expression levels of SLUG and TWIST between tumor 
center and tumor periphery was seen [23].
Spatial intra-tumoral heterogeneity has been described 
in connection with epithelial-mesenchymal transition 
(EMT), as breast cancer genome has been shown to 
change dynamically during cancer development from 
primary to metastatic tumor [24]. EMT is a process dur-
ing which epithelial cells lose their epithelial cell charac-
teristics and acquire mesenchymal phenotype and EMT 
cells gain motility and become invasive [25–29]. Hence, 
EMT has been considered as an important mechanism in 
tumor cell progression and metastasis, and consistently, 
the expression of EMT markers has been shown to be 
associated with poor prognosis [25–29]. There is increas-
ing evidence that EMT is associated with acquisition of 
stem-cell properties [29, 30]. In a study of well-differ-
entiated colorectal cancers and their metastasis a dedif-
ferentiation and loss of epithelial properties was seen at 
the invasive tumor margin, and Brabletz et  al. therefore 
proposed occurrence of EMT preferably at peripheral 
tumor sites [23, 31]. However, this hypothesis could not 
be confirmed by Alkatout et al. No significant difference 
of expression levels of the EMT markers SLUG, TWIST, 
SNAIL and Zeb1 between tumor center and tumor 
periphery could be revealed [23]. On the other hand, 
Connor et al. found a higher proliferative activity (Ki-67 
index) at the tumor periphery than in the tumor center 
[32]. As described above, our results are in accordance to 
the data of Alkatout et al. We could not find a difference 
of expression levels of SLUG and TWIST between tumor 
center and periphery either. A possible interpretation of 
these findings is that epithelial-mesenchymal transition is 
not only occurring at the tumor periphery, but at multi-
ple sites within the tumor [23].
The second aim of the study was to proof prognos-
tic value of the special TMA containing different tumor 
areas by comparing expression levels of conventional 
predictive tumor markers, tumor progression markers 
and stem cell markers with histopathological grading. In 
breast cancer diagnostics hormone receptors (ER, PR) 
as well as HER2 are established prognostic and predic-
tive biomarkers [33–35]. Based on the current TMA, we 
could proof a strong negative correlation between hor-
mone receptor expression levels and histopathological 
grading and a significant positive correlation between 
histopathological grading and HER2/EGFR/CK5/6 
expression, corresponding with literature data and con-
firming prognostic value of the TMA independently of 
the site of the biopsy was taken.
Ki-67 and p53 are connected to cell proliferation and 
if increased or overexpressed are associated with higher 
grading, metastatic potential and shortened overall-
survival [33, 35–37]. A shortened time to progression 
and decreased survival has furthermore been seen with 
PTEN deletion and PIK3CA activating mutations [38, 
39]. In accordance with these findings we found a signifi-
cant positive correlation between Ki-67, p53 and PIK3CA 
expression levels and histopathological grading, whereas 
a negative correlation was seen with PTEN expression.
Previous studies about the predictive value of CD44 
and CD24 have showed controversial results. In 2003, a 
CD44+/CD24− phenotype was first identified as a highly 
tumorigenic subpopulation of tumor cells with stem-cell-
like characteristics [5, 6, 8]. Tumors showing this phe-
notype were described to favor occurrence of distant 
metastasis, but no significant correlation with clinical 
outcome was seen [40–43]. In studies separately analyz-
ing CD44 as a predictive marker an association between 
CD44 positivity and increased progression-free and dis-
ease-free survival was found [44, 45]. The role of CD24 as 
a predictive marker was as well discussed controversial. 
Fig. 10 p-value histogram from the differential expression analysis. 
Absent and present genes in the data are separated by the color
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The data of Kristiansen et  al. revealed an association to 
shortened disease-free-survival, while Jang et  al. found 
no significant correlation to prognosis [46, 47]. In our 
study, a slight respectively strong negative correlation 
between CD44 and CD24 and histopathological grading 
was seen, being concordant with the results of Dan et al. 
and Diaz et al.
TWIST, SLUG and SOX9 have lately been described as 
cancer stems cell markers inducing EMT [48–51]. In con-
sistence with our findings, previous studies found these 
markers to be associated with higher histopathological 
grading and shortened overall survival [48, 50–55].
Through loss of E-cadherin tumor cells gain the ability 
to migrate and E-cadherin negativity was found to cor-
relate with higher tumor grade and stage and poor prog-
nosis [56, 57]. However, in contrast to these results, our 
data revealed a positive correlation to histopathological 
grading.
SOX2 and SOX10 are often present in breast can-
cer, although their role is poorly understood yet. Our 
data further support recent suggestions that SOX2 and 
SOX10 correlate to higher histopathological grading and 
hence to reduced overall survival [51, 58].
mTOR is part of a pathway playing an important role 
in tumorigenesis. Our findings are in agreement with a 
recent study of Ding et  al. where no significant correla-
tion between mTOR expression and clinical outcome was 
seen [59].
Intratumoral heterogeneity of tumor infiltrating lym-
phocytes (TIL) was addressed in a previous study assess-
ing different anatomical regions of breast cancer on large 
tissue sections and showing that TIL-s at the infiltrating 
margins are more numerous than in the intratumoral 
stromal tissue [60]. Interestingly, the same trend was 
found when metastatic lesions were compared with the 
primary tumor suggesting that the primary tumor most 
likely determines the TIL composition in the metastatic 
lesion which mirrors the immunological pattern of pri-
mary tumor [60].
Regarding the correlation between stem cell, tumor 
progression and conventional prognostic markers, we 
could show in our study, that within the current TMA 
cohort most markers displayed significant inter-marker 
correlation, independently from the anatomical site of 
the tumor sample taken. Most breast tumors are estro-
gen receptor and progesterone receptor positive and are 
associated with better overall survival. Further, HER2 
negativity was found to correlate with ER and PR posi-
tivity and was as well described to be associated with 
favorably prognosis [33, 35, 38]. Ki-67, as a prolifera-
tion marker, as well as p53 are linked with poor prog-
nosis. Their expression levels negatively correlate with 
ER and PR expression levels and positively correlate 
with HER2 status [33, 37, 61, 62]. All these findings are 
in complete agreement with the results of our study, 
where a strong significant correlation between the hor-
mone receptors and a negative correlation between ER/
PR and HER2, Ki-67 and p53 was seen. On the other 
hand, no correlation was found between p53 and Ki-67 
expression levels.
Trastuzumab is a monoclonal antibody, used for treat-
ment of metastatic HER2-positive breast cancer. Lately, 
it was suggested that mutations of the PI3 K/AKT path-
way and loss of PTEN could interfere with trastuzumab 
treatment and lead to resistance. Recent studies therefore 
questioned whether PIK3CA and PTEN could be used as 
predictive markers of trastuzumab efficacy [38, 63]. We 
revealed a strong significant correlation between HER2 
status and PTEN expression level and between PTEN 
and PIK3CA but not between HER2 status and PIK3CA 
expression level was seen. The results agreed with previ-
ous studies of Razis et al. and Lebok et al., where as well a 
correlation between HER2 and PTEN was found [38, 39]. 
So far, PTEN loss and PIK3CA mutations are proposed 
to be mutually exclusive, what seems to be inconsistent 
with our finding of a significant correlation between the 
two markers, even though mutation status of PIK3CA 
was not assessed in our study [38]. However in one recent 
study by Sueta et  al., a combined analysis of PTEN loss 
and PIK3CA mutations was shown to potentially iden-
tify patients who are unlikely to respond to trastuzumab 
therapy in neoadjuvant setting [64]. It seems, that com-
plete pathological response, pCR is lower if an activating 
PIKC3CA mutation and/or low level or PTEN expres-
sion is present [64]. PTEN is a negative regulator of the 
PIK3CA pathway, consequently, simultaneous PIK3CA 
mutations and low PTEN expression can stronger predict 
response to trastuzumab therapy then one marker alone, 
which can potentially identify patients who can benefit 
from PIK3  K targeted therapies [64]. The negative and 
positive correlation between PIKC3CA and PTEN pro-
tein expression and gene copy numbers in our study cor-
roborate with these observations.
So far, only few studies investigated the association of 
CD24/CD44 to other markers. Collina et  al. described 
a slight statistical link between CD44 and Ki-67, which 
could not be confirmed by our study [43]. Jang et al. pre-
viously found a negative, respectively positive correlation 
between CD44/CD24 and HER2 status [47]. Our data 
revealed as well an inverse correlation between HER2 
and CD44, but inconsistent with the results of Jang et al. 
an inverse association to CD24 too.
The over-expression of most stem cell markers has 
been linked to poor prognosis and to hormone recep-
tor negativity and HER2 positivity, which also could be 
confirmed in our data [48, 54, 56, 58, 65]. The numerous 
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correlations among the stem cell markers, further provid-
ing a similar predictive value [48, 54, 56, 58, 65].
Conclusion
Based on the data in our study, a tissue micro array 
based approach failed to deliver sufficient information 
on intra-tumoral heterogeneity in breast cancer stem cell 
and tumor progression markers by comparing central 
and peripheral tumor areas. Further studies using single 
cell genomic alterations including further mRNA based 
assessments are needed to fully understand the role and 
interaction between stem cell marker and intra-tumoral 
heterogeneity also in terms of tumor progression in 
breast cancer. On the other hand, the anatomical site of 
the tumor samples did not influence prognostic informa-
tion on these markers which was independent from the 
site of biopsy was taken.
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